PD-1 Resistant Head and Neck Cancer (HNC) Market Landscape Report 2021
August 31, 2021 04:08 ET | Source: Research and Markets
...
Dublin, Aug. 31, 2021 (GLOBE NEWSWIRE) -- The "PD-1 Resistant Head and Neck Cancer (HNC) - Market Insight, Epidemiology and Market Forecast 2030" report has been added to ResearchAndMarkets.com's offering.
The PD-1 Resistant Head and Neck Cancer market report provides current treatment practices, emerging drugs, and their market share of the individual therapies, current and forecasted PD-1 Resistant Head and Neck Cancer symptoms market size from 2018 2030 segmented by the major markets.
The report also covers current PD-1 Resistant Head and Neck Cancer symptoms treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities. It assesses the underlying potential of the market.
Country-wise PD-1 Resistant Head and Neck Cancer Epidemiology
The epidemiology segment also provides the PD-1 Resistant Head and Neck Cancer epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan, China, South Korea, and Taiwan.
The total incident cases of PD-1 refractory patients of PD-1 Resistant Head and Neck Cancer-associated in the mentioned countries was 11,940 in 2020.
PD-1 Resistant Head and Neck Cancer Drug Chapters
The PD-1 Resistant Head and Neck Cancer report's drug chapter segment encloses the detailed analysis of PD-1 Resistant Head and Neck Cancer's early-stage (Phase I, II, and III) pipeline drugs. It also helps understand the PD-1 Resistant Head and Neck Cancer clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.
PD-1 Resistant Head and Neck Cancer Emerging Drugs
Monalizumab (IPH2201): AstraZeneca/Innate Pharma
Monalizumab (IPH2201) is a potentially first-in-class immune checkpoint inhibitor targeting NKG2A receptors expressed on tumor-infiltrating cytotoxic CD8+ T-cells and NK cells. NKG2A is an inhibitory checkpoint receptor for HLA-E. By expressing HLA-E, cancer cells can protect themselves from killing by NKG2A+ immune cells. HLA-E is frequently overexpressed on cancer cells of many solid tumors and hematological malignancies.
Buparlisib: Adlai Nortye Biopharma
Buparlisib is an oral pan-PI3K inhibitor that targets all class I PI3K isoforms and is active in both hematologic malignancies and solid tumors. Buparlisib significantly inhibited tumor growth in the animal model and showed a dose-response trend in anti-PD-1 refractory tumor-bearing mice. The dose range of buparlisib was consistent with previous preclinical studies conducted with BKM120 (Buparlisib, AN2025) by Novartis.
PD-1 Resistant Head and Neck Cancer Market Outlook
The PD-1 Resistant Head and Neck Cancer market outlook helps build a detailed comprehension of the historical, current, and forecasted PD-1 Resistant Head and Neck Cancer market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and demand for better technology.
This segment gives a thorough detail of PD-1 Resistant Head and Neck Cancer market trend of each marketed drug and early-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
Although ICI is a successful new approach in cancer therapy, these checkpoint inhibitors may also lead to a loss of immune tolerance of healthy tissue, which results in various side effects, referred to as immune-related adverse events (irAEs). According to few references, up to one-fourth of patients on ipilimumab monotherapy and about the same percentage of patients on combined therapy suffer from severe (grade 3 or 4) enterocolitis. According to Burla (2020), overall, 15-25% of patients on single immunotherapy and about 65% of patients on combined immunotherapy suffer from grade 3 or grade 4 irAEs.
Immuno-oncology agents, including immune checkpoint inhibitors (ICIs), have revolutionized the treatment of a range of cancer types. Checkpoint molecules suppress T-cell function through various mechanisms and are exploited by tumor cells to evade the host immune attack. ICIs counteract this immunosuppression and restore immune responses against cancer.
